Training Grant in Cancer Biology

癌症生物学培训补助金

• 批准号: 10493466
• 负责人: Toni M Antalis
• 金额: $ 50.72万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493466
• 关键词: Cancer Biology; Grant; Training

This revised application seeks renewal for Years 11-15 of the Training Program in Cancer Biology (T32CB) in the Greenebaum Comprehensive Cancer Center (UMGCCC) at the University of Maryland Baltimore (UMB). We are requesting support for 4 predoctoral students and 4 postdoctoral fellows each year. To enrich the T32CB, UMGCCC will provide an additional postdoc position, especially an underrepresented minority, raising the total T32CB postdoc slots to 5/year. T32CB focuses on multidisciplinary cancer biology research training with a translational mission. Our objectives are: 1) to provide productive bidirectional translation between lab and clinic through research and didactic sessions, 2) to provide outstanding training in critical areas of contemporary basic and translational cancer research and 3) to recruit and retain a strong group of expert faculty mentors to enable networked productivity of trainees. These objectives are accomplished in a carefully structured program that ensures individual flexibility with specific cancer-focused components. The 36 mentors were selected from UMGCCC faculty based on their published scientific achievements, track record of research funding, interest in translational cancer research and experience in mentoring trainees. The predoc component, which includes PhD and MD/PhD scholars, builds from and enhances training in the Cancer Biology Track of the Graduate Program in Life Sciences (GPILS). The postdoc component provides research training for PhD, MD and MD/PhD postdocs, including physician-scientists during the research years of Surgery residency or Hematology/Medical Oncology fellowship training. A longstanding T32CB strength is integration of predoc students, postdoc PhD- scientists, and physician-scientists who participate side-by-side in journal clubs (JC), in research-in-progress (RIP) seminars and at the bench in laboratories. The T32CB enjoys strong institutional support and an outstanding research training environment, with collaborative relationships between translational and basic cancer research faculty and access to cutting-edge technologies that facilitate specialized research activities. Based on program evaluations, several innovations are proposed in this renewal application, including expanded training in cancer genomics/bioinformatics and exposure to cancer bioengineering. Professional development opportunities prepare all trainees for the next stages in their careers. The T32CB training record is extremely strong: trainees publish productively and are recipients of awards, grants and fellowships. The effectiveness of our mission to train the next generation of cancer researchers is high, with 100% of T32CB graduates continuing in research-related careers. The T32CB leverages UMGCCC’s emphasis on cancer disparities to attract and train underrepresented minorities at a high rate (18%). A new Diversity Advisory Committee will further enhance T32CB recruitment and retention of highly qualified trainees from diverse backgrounds. Our team science approach, guided by stellar mentors, enables our talented physician- and PhD-scientists to create and contribute to transdisciplinary science that is likely to yield innovative benefits for cancer patients.

此修订后的申请寻求续签癌症生物学培训计划 (T32CB) 的第 11-15 年 马里兰大学巴尔的摩分校 (UMB) 的格林鲍姆综合癌症中心 (UMGCCC)。我们 每年请求支持 4 名博士前学生和 4 名博士后研究员。为了丰富T32CB， UMGCCC 将提供额外的博士后职位，特别是代表性不足的少数群体，从而提高博士后职位总数 T32CB 博士后名额为每年 5 个。 T32CB 专注于多学科癌症生物学研究培训 翻译使命。我们的目标是：1) 在实验室和诊所之间提供高效的双向翻译 通过研究和教学课程，2）在当代基础知识的关键领域提供出色的培训 和转化癌症研究，以及 3) 招募和留住一支强大的专家导师团队，以实现 学员的网络生产力。这些目标是通过精心构建的计划来实现的，该计划 通过特定的癌症重点成分确保个人灵活性。 36位导师是从 UMGCCC 教师基于他们发表的科学成果、研究经费的记录、对 转化癌症研究和指导学员的经验。 predoc 部分，包括 Ph.D. 和医学博士/博士学者，以研究生项目的癌症生物学轨道为基础并加强培训 生命科学（GPILS）。博士后部分为博士、医学博士和医学博士/博士提供研究培训 博士后，包括外科住院医师或血液学/医学研究期间的医师科学家 肿瘤学奖学金培训。 T32CB 的长期优势是博士前学生、博士后博士生的整合 并肩参加期刊俱乐部 (JC)、正在进行的研究的科学家和医师科学家 （RIP）研讨会和实验室的工作台。 T32CB 享有强大的机构支持和 出色的研究培训环境，具有转化和基础之间的协作关系 癌症研究人员和获得促进专门研究活动的尖端技术的机会。 根据项目评估，本次续展申请提出了多项创新，包括扩展 癌症基因组学/生物信息学和癌症生物工程方面的培训。专业发展 机会让所有学员为职业生涯的下一阶段做好准备。 T32CB的训练记录极其 强：受训者发表富有成效的文章，并获得奖项、助学金和研究金。的有效性 我们培养下一代癌症研究人员的使命很高，100% 的 T32CB 毕业生继续 从事与研究相关的职业。 T32CB 利用 UMGCCC 对癌症差异的重视来吸引和 对代表性不足的少数群体进行高比例的培训（18%）。新的多元化咨询委员会将进一步加强 T32CB 招聘和保留来自不同背景的高素质学员。我们的团队科学 在杰出导师的指导下，我们的才华横溢的医生和博士科学家能够创造并做出贡献 跨学科科学可能为癌症患者带来创新益处。